TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35186274

Group type: EXPERIMENTAL
Intervention: Pepsi
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mirinda
Number of subjects: 36

Group type: COMPARATOR
Intervention: Artificial saliva
Number of subjects: 36
Study: 32594949

Group type: EXPERIMENTAL
Intervention: Metabolisable energy intake (MEI)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Utilisation efficiency for egg production (ko)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Utilisation efficiency (kt)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Net energy requirement for weight gain (WG)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Egg mass (EM)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Retained energy (RE)
Number of subjects: 300
Study: 35507945

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 656

Group type: COMPARATOR
Intervention: venetoclax and azacitidine (ven/aza)
Number of subjects: 656
Study: 33431807

Group type: EXPERIMENTAL
Intervention: Visuospatial cognitive task 'Tetris' with mental rotation instructions
Number of subjects: 41

Group type: COMPARATOR
Intervention: Podcast (active control)
Number of subjects: 41
Study: 34253433

Group type: EXPERIMENTAL
Intervention: Percutaneous prodding reduction and K‐wire fixation via sinus tarsi approach (PPRKF)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both PPRKF and ORIF
Number of subjects: 51
Study: 33743650

Group type: EXPERIMENTAL
Intervention: PRP plus physiotherapy
Number of subjects: 314

Group type: COMPARATOR
Intervention: PRP
Number of subjects: 314
Study: 34347057

Group type: EXPERIMENTAL
Intervention: Graphic Warning Labels (GWL) cigarette packs
Number of subjects: 357

Group type: COMPARATOR
Intervention: Standard US pack
Number of subjects: 357

Group type: COMPARATOR
Intervention: Blank pack
Number of subjects: 357
Study: 36484428

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg for 13 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo for 13 weeks
Number of subjects: 90
Study: 33592849

Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32167240

Group type: EXPERIMENTAL
Intervention: Products A and B
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control X
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Product C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Y
Number of subjects: 30
Study: 34726329

Group type: EXPERIMENTAL
Intervention: HM15136 (10-120 μg/kg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: HM15136 (80 μg/kg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: HM15136 (50 μg/kg or higher)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: HM15136
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 34100789

Group type: EXPERIMENTAL
Intervention: Low velocity loss (LVL) threshold at 15%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High velocity loss (HVL) threshold at 30%
Number of subjects: 10
Study: 32301204

Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (1,000 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose/day)
Number of subjects: 20
Study: 35077818

Group type: EXPERIMENTAL
Intervention: Patient-Specific Instrumentation (PSI)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Traditional cutting block techniques (Control)
Number of subjects: 77
Study: 33573704

Group type: EXPERIMENTAL
Intervention: Total CCFN (H3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: H3K36me3
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: H3 citrulline
Number of subjects: 40
Study: 32012409

Group type: COMPARATOR
Intervention: 0.4 mg tamsulosin only (Group-A)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil with tamsulosin (Group-B)
Number of subjects: 140
Study: 34709770

Group type: EXPERIMENTAL
Intervention: Type-1 collagen cone (CC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no collagen cone)
Number of subjects: 30
Study: 33186772

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) 10 mg per day for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 34076329

Group type: EXPERIMENTAL
Intervention: Negative event with counterfactual
Number of subjects: 466

Group type: COMPARATOR
Intervention: Negative event only
Number of subjects: 466

Group type: COMPARATOR
Intervention: Negative event with description
Number of subjects: 466

Group type: COMPARATOR
Intervention: Control
Number of subjects: 466
Study: 33289308

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 63
Study: 35469091

Group type: EXPERIMENTAL
Intervention: BCAA (12 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32317292

Group type: EXPERIMENTAL
Intervention: NY‐ESO‐1/ISCOMATRIX vaccine
Number of subjects: 110

Group type: COMPARATOR
Intervention: ISCOMATRIX alone
Number of subjects: 110
Study: 34480530

Group type: EXPERIMENTAL
Intervention: Preoperative systemic chemotherapy
Number of subjects: 2150

Group type: COMPARATOR
Intervention: Resection alone (control)
Number of subjects: 2150
Study: 33884043

Group type: EXPERIMENTAL
Intervention: Experimental group (EXP) focusing on interoceptive correlates
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 34981548

Group type: EXPERIMENTAL
Intervention: Low-intensity, long-wavelength red light therapy (LLRT) (power 0.4 mW, wavelength 635 nm) twice per day for 3 min each session
Number of subjects: 105
Study: 33984253

Group type: EXPERIMENTAL
Intervention: G80 (2 sets at 80% and 2 sets at 40% of 1 repetition maximum (1RM), 1 concentric second and 3 eccentric seconds controlled by a metronome)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G40 (4 sets at 40% of 1RM, 1 s and 3 s controlled by a metronome)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 32654603

Group type: EXPERIMENTAL
Intervention: HA-SA combined with NPWT (n=11)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional therapy (n=14)
Number of subjects: 25
Study: 35870999

Group type: EXPERIMENTAL
Intervention: Trauma-focused CBT with positive memory module
Number of subjects: 135

Group type: COMPARATOR
Intervention: Trauma-focused CBT without positive memory module
Number of subjects: 135

Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 135
Study: 33905748

Group type: EXPERIMENTAL
Intervention: Spherical soft contact lenses (–6 D to +6 D in 2 D steps)
Number of subjects: 11
Study: 33167111

Group type: EXPERIMENTAL
Intervention: Intramedullary nail
Number of subjects: 37

Group type: COMPARATOR
Intervention: Locking plate
Number of subjects: 37
Study: 32977331

Group type: EXPERIMENTAL
Intervention: SCFP (Saccharomyces cerevisiae fermentation-based postbiotic)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCON (control group without SCFP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SCFP
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCON
Number of subjects: 60
Study: 32436390

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 1605

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: TAVR and SAVR
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Procedural outcomes
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Non-procedural outcomes
Number of subjects: 1605
Study: 33377160

Group type: EXPERIMENTAL
Intervention: Lowest tertile of baseline serum bicarbonate (23.1 ± 1.6 mmol/L)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Each mmol/L decrease in serum bicarbonate
Number of subjects: 296
Study: 35587779

Group type: EXPERIMENTAL
Intervention: Low-energy meal-replacement plan (MRP) (∼810 kcal/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Exercise training
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 83
Study: 34508569

Group type: EXPERIMENTAL
Intervention: Exercise training for 3 months
Number of subjects: 51
Study: 32366328

Group type: EXPERIMENTAL
Intervention: Usual care plus Proactive Psychological Medicine (PPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usual care plus PPM
Number of subjects: 0
Study: 35392020

Group type: EXPERIMENTAL
Intervention: Multi-channel tDCS, Functional electrical stimulation, Saebo Flex Training, and conventional rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham multi-channel tDCS, FES, training with SaeboFlex, and conventional physiotherapy intervention
Number of subjects: 0
Study: 32792245

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) combined with NSAIDs
Number of subjects: 80

Group type: COMPARATOR
Intervention: NSAIDs alone (Control group)
Number of subjects: 80
Study: 33047637

Group type: EXPERIMENTAL
Intervention: Thyroid autoimmunity group (n = 39)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (n = 46)
Number of subjects: 85
Study: 32073417

Group type: EXPERIMENTAL
Intervention: Intracoronary prourokinase administration
Number of subjects: 0
Study: 34144574

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the affected hemisphere and cathodal over unaffected hemisphere combined with repetitive peripheral nerve stimulation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham tDCS associated to repetitive peripheral nerve stimulation
Number of subjects: 19
Study: 33392782

Group type: EXPERIMENTAL
Intervention: 940 nm laser diode irradiation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (aiming beam only)
Number of subjects: 30
Study: 32993574

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy and cetuximab
Number of subjects: 315

Group type: COMPARATOR
Intervention: Radiotherapy and cetuximab
Number of subjects: 315
Study: 35093013

Group type: EXPERIMENTAL
Intervention: Atogepant 10 mg
Number of subjects: 2466

Group type: EXPERIMENTAL
Intervention: Atogepant 30 mg
Number of subjects: 2466

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2466
Study: 34922475

Group type: EXPERIMENTAL
Intervention: Remote activity monitoring (RAM) system
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (no RAM)
Number of subjects: 179
Study: 32567433

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 13

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 13
Study: 35342790

Group type: EXPERIMENTAL
Intervention: Self-guided PowerPoint tutorial on head and neck anatomy
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (no tutorial engagement)
Number of subjects: 178
Study: 33032564

Group type: EXPERIMENTAL
Intervention: Online exercise programme and diet counselling on calcium and vitamin D.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Diet counselling only (Control group).
Number of subjects: 116
Study: 36124913

Group type: EXPERIMENTAL
Intervention: Barley bread (BB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oat bread (OB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whole-wheat bread (WWB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: White bread (WB)
Number of subjects: 20
Study: 33589569

Group type: EXPERIMENTAL
Intervention: Energy-reduction group (ERG)
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Calcium supplementation group (CSG)
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Energy-reduction with calcium supplementation group (ER-CSG)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 1021
Study: 35379311

Group type: EXPERIMENTAL
Intervention: Retromuscular Sugarbaker technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retromuscular keyhole technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 34558301

Group type: EXPERIMENTAL
Intervention: Intervention group (tweeting/retweeting health content 2 times/week for 6 months)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 611
Study: 32369830

Group type: EXPERIMENTAL
Intervention: Quality indicator performance assessment
Number of subjects: 3383

Group type: EXPERIMENTAL
Intervention: Patient characteristics (gender, number of treating general practitioners, number of comorbidities, number of consultations)
Number of subjects: 3383
Study: 34358514

Group type: EXPERIMENTAL
Intervention: Topical application of 3%, 5%, 10%, and 15% Piper guineense oil
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Topical application of 10% and 15% Piper guineense oil
Number of subjects: 100
Study: 34935955

Group type: EXPERIMENTAL
Intervention: Colorimetric method
Number of subjects: 0

Group type: COMPARATOR
Intervention: RP-HPLC method
Number of subjects: 0

Group type: COMPARATOR
Intervention: TLC-densitometric method
Number of subjects: 0
Study: 34468691

Group type: EXPERIMENTAL
Intervention: Self-chosen and immediate goals
Number of subjects: 500

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 500
Study: 35411401

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 86

Group type: COMPARATOR
Intervention: PI
Number of subjects: 86
Study: 33829271

Group type: EXPERIMENTAL
Intervention: 1.2 mg thiamine daily
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: 2.4 mg thiamine daily
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: 10 mg thiamine daily
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo (0 mg thiamine)
Number of subjects: 335
Study: 35701386

Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 52

Group type: COMPARATOR
Intervention: Femoral blocks (19 fascia iliaca compartment blocks, 14 femoral nerve blocks)
Number of subjects: 52
Study: 33849658

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Active tDCS + CR
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham tDCS + CR
Number of subjects: 26

Group type: COMPARATOR
Intervention: Treatment as usual (waiting period)
Number of subjects: 26
Study: 32408253

Group type: EXPERIMENTAL
Intervention: Amino acids (Arginine and Leucine) administered for 10 weeks at a dosage of 0.1 g/kg body mass/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined group (placebo + AAs)
Number of subjects: 12
Study: 33867108

Group type: EXPERIMENTAL
Intervention: SBAR role-play training
Number of subjects: 0
Study: 32333512

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser combined with intradermal injection of PRP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intraderma injection of noncross-linked hyaluronic acid
Number of subjects: 30
Study: 35279181

Group type: EXPERIMENTAL
Intervention: Direct anterior approach combined with direct posterior approach
Number of subjects: 64

Group type: COMPARATOR
Intervention: Direct anterior approach
Number of subjects: 64
Study: 34749717

Group type: EXPERIMENTAL
Intervention: Gout-storytelling intervention
Number of subjects: 306

Group type: COMPARATOR
Intervention: Stress reduction video (attention control)
Number of subjects: 306
Study: 36165508

Group type: EXPERIMENTAL
Intervention: Cilostazol (50 mg daily, increased to 100 mg/day after 2 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 33899498

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 5 mg
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 5 mg and metoclopramide 10 mg
Number of subjects: 138

Group type: COMPARATOR
Intervention: Intravenous placebo (control group)
Number of subjects: 138
Study: 32333527

Group type: EXPERIMENTAL
Intervention: Liver transplantation with extended criteria donor grafts
Number of subjects: 10
Study: 36113693

Group type: EXPERIMENTAL
Intervention: High intensity exercise group (HEX)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low intensity exercise group (LEX)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waiting list control group (WL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (HEX, LEX, WL)
Number of subjects: 120
Study: 32705528

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy for 1 month
Number of subjects: 64

Group type: COMPARATOR
Intervention: N/A (Control group untreated)
Number of subjects: 64

Group type: COMPARATOR
Intervention: N/A (Non-OSA control group)
Number of subjects: 64
Study: 36103251

Group type: EXPERIMENTAL
Intervention: Universidade do Bebê (UBB) intervention consisting of monthly workshops focused on reading aloud and a book-lending library
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Universidade do Bebê (UBB) intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study: 33086286

Group type: EXPERIMENTAL
Intervention: TF-CBT and exercise
Number of subjects: 103

Group type: COMPARATOR
Intervention: ST and exercise
Number of subjects: 103
Study: 32100656

Group type: COMPARATOR
Intervention: Non-intervened arm of a randomised controlled trial of pro-vitamin A carotenoid biofortified maize
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Season
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Recall on a market day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Unadjusted within-to-between-person variance ratios
Number of subjects: 200
Study: 36028920

Group type: EXPERIMENTAL
Intervention: Standardized KS clinical evaluation tool, palliative care integration, standardized treatment, improved consultative services
Number of subjects: 1102
Study: 34602640

Group type: EXPERIMENTAL
Intervention: Hydromorphone 0.1 mg/kg BW intramuscularly (IM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydromorphone 0.01 mg/kg BW pharmacopuncture at GV20 (GV)
Number of subjects: 50
Study: 35157529

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12
Study: 33184972

Group type: EXPERIMENTAL
Intervention: Hypoglossal Neurostimulation therapy (HGNS)
Number of subjects: 15
Study: 35249338

Group type: EXPERIMENTAL
Intervention: Sodium pyruvate (PYR) supplementation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Maltodextrin placebo (PLA)
Number of subjects: 14
Study: 34985149

Group type: EXPERIMENTAL
Intervention: Experiences of living with Charcot neuroarthropathy (CN)
Number of subjects: 14
Study: 32199338

Group type: EXPERIMENTAL
Intervention: Negative pressure dressing
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional wound dressing
Number of subjects: 62
Study: 34078635

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) knowledge
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Positive attitude towards EBM
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Good level of EBM practice
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Factors associated with EBM practice
Number of subjects: 225
Study: 35939102

Group type: EXPERIMENTAL
Intervention: Instillation of 2% lidocaine in the gallbladder bed after removal of the gallbladder
Number of subjects: 82

Group type: COMPARATOR
Intervention: Subcutaneous injection of 2% lidocaine at the port sites before incision
Number of subjects: 82
Study: 34999348

Group type: EXPERIMENTAL
Intervention: Topical application of recombinant human basic fibroblast growth factor (bFGF) + conventional medication
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional medication
Number of subjects: 100
Study: 33427546

Group type: EXPERIMENTAL
Intervention: E6011 400-mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 32565444

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM; 15 mg/kg bodyweight)
Number of subjects: 48
Study: 32648390

Group type: EXPERIMENTAL
Intervention: Yin-yang balance penetrating acupuncture combined with rehabilitation training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rehabilitation training (Control group)
Number of subjects: 60
Study: 33476301

Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies to SARS-CoV-2
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: RBD-IgG levels
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IgG levels against RBD and nucleocapsid protein
Number of subjects: 104
Study: 32844540

Group type: EXPERIMENTAL
Intervention: High dialysate magnesium (1.0 mmol/L)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low dialysate magnesium (0.5 mmol/L)
Number of subjects: 20
Study: 33957183

Group type: EXPERIMENTAL
Intervention: FYB201
Number of subjects: 477

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 477

Group type: COMPARATOR
Intervention: FYB201 vs Ranibizumab
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 477
Study: 33319628

Group type: EXPERIMENTAL
Intervention: γ‐T‐rich vitamin E mixture (two capsules daily for 7 or 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 0
Study: 34418014

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 15mg/Kg administered 15-30 minutes pre-surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl 2mcg/kg administered at induction of anaesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 33227004

Group type: EXPERIMENTAL
Intervention: A Germ's Journey educational resources (multicomponent intervention)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: A Germ's Journey song intervention
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group (Study 1)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group (Study 2)
Number of subjects: 329
Study: 35264846

Group type: EXPERIMENTAL
Intervention: Inhaled velsecorat (1872 µg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Inhaled velsecorat
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 33098463

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10